Gima Lauren, Solomon Ilana, Hampel Heather
Division of Clinical Cancer Genomics, City of Hope National Medical Center, Duarte, California.
Clin Colon Rectal Surg. 2023 Jul 19;37(3):133-139. doi: 10.1055/s-0043-1770381. eCollection 2024 May.
The field of cancer genetics has evolved significantly over the past 30 years. Genetic testing has become less expensive and more comprehensive which has changed practice patterns. It is no longer necessary to restrict testing to those with the highest likelihood of testing positive. In addition, we have learned that the criteria developed to determine who has the highest likelihood of testing positive are neither sensitive nor specific. As a result, the field is moving from testing only the highest risk patients identified based on testing criteria to testing all cancer patients. This requires new service delivery models where testing can be mainstreamed into oncology clinics and posttest genetic counseling can be provided to individuals who test positive and those with concerning personal or family histories who test negative. The use of videos, testing kiosks, chatbots, and genetic counseling assistants have been employed to help facilitate testing at a larger scale and have good patient uptake and satisfaction. While testing is important for cancer patients as it may impact their treatment, future cancer risks, and family member's cancer risks, it is unfortunate that their cancer could not be prevented in the first place. Population testing for all adults would be a strategy to identify individuals with adult-onset diseases before they develop cancer in an attempt to prevent it entirely. A few research studies (Healthy Nevada and MyCode) have offered population testing for the three Centers for Disease Control and Prevention Tier 1 conditions: hereditary breast and ovarian cancer syndrome, Lynch syndrome, and familial hypercholesterolemia finding a prevalence of 1 in 70 individuals in the general population. We anticipate that testing for all cancer patients and the general population will continue to increase over the next 20 years and the genetics community needs to help lead the way to ensure this happens in a responsible manner.
在过去30年里,癌症遗传学领域有了显著发展。基因检测变得更便宜且更全面,这改变了医疗实践模式。不再需要将检测局限于检测呈阳性可能性最高的人群。此外,我们了解到,用于确定谁检测呈阳性可能性最高的标准既不敏感也不特异。因此,该领域正从仅对根据检测标准确定的最高风险患者进行检测,转向对所有癌症患者进行检测。这需要新的服务提供模式,使检测能够融入肿瘤诊所的主流,并为检测呈阳性的个体以及检测呈阴性但有相关个人或家族病史的个体提供检测后遗传咨询。视频、检测亭、聊天机器人和遗传咨询助手的使用,有助于在更大规模上推动检测,且患者接受度高、满意度好。虽然检测对癌症患者很重要,因为它可能影响其治疗、未来患癌风险以及家庭成员的患癌风险,但遗憾的是,他们的癌症从一开始就无法预防。对所有成年人进行群体检测将是一种策略,即在个体患成年发病疾病并发展为癌症之前识别他们,试图完全预防癌症。一些研究(内华达健康计划和我的基因计划)针对美国疾病控制与预防中心的三类一级疾病提供了群体检测:遗传性乳腺癌和卵巢癌综合征、林奇综合征和家族性高胆固醇血症,发现普通人群中患病率为七十分之一。我们预计,在未来20年里,对所有癌症患者和普通人群的检测将持续增加,遗传学领域需要引领方向,以确保这一过程以负责任的方式进行。